Health Affairs, 24, no. 3 (2005): 706-717 doi: 10.1377/hlthaff.24.3.706 © 2005 by Project HOPE	New Online   Senate Health Reform Bill   Rewarding Providers   Public Option Policy Brief   Health Reform & Abortion   Delivery System Reform

This Article Full Text (HTML) Reprint (PDF) Supplemental Exhibits Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Danzon, P. M. Articles by Tejwani, S. S. Search for Related Content PubMed PubMed Citation Articles by Danzon, P. M. Articles by Tejwani, S. S. Related Collections Health Promotion/Disease Prevention International Issues Public Health Research And Technology Consumer Issues Vaccines

Implementation

Vaccine Supply: A Cross-National Perspective

In U.S. vaccine markets, competing producers with high fixed, sunk costs face relatively concentrated demand. This tends to lead to exit of all but one or very few producers per vaccine. Detailed evidence of exits and shortages in the flu vaccine market demonstrates the importance of high fixed costs, demand uncertainty, and dynamic quality competition. A comparison of vaccine suppliers in four industrialized countries compared with the United States shows that smaller foreign markets often have more and different vaccine suppliers. High, country-specific, fixed costs, combined with price and volume uncertainty, plausibly deters these potential suppliers from attempting to enter the U.S. market.

                      What's this?

This article has been cited by other articles:

				B.-K. Yoo, M. Kasajima, K. Fiscella, N. M. Bennett, C. E. Phelps, and P. G. Szilagyi Effects of an Ongoing Epidemic on the Annual Influenza Vaccination Rate and Vaccination Timing Among the Medicare Elderly: 2000-2005 Am J Public Health, October 1, 2009; 99(S2): S383 - S388. [Abstract] [Full Text] [PDF]

				S. Deo and C. J. Corbett Cournot Competition Under Yield Uncertainty: The Case of the U.S. Influenza Vaccine Market MSOM, October 1, 2009; 11(4): 563 - 576. [Abstract] [PDF]

				L. O. Gostin Medical Countermeasures for Pandemic Influenza: Ethics and the Law JAMA, February 1, 2006; 295(5): 554 - 556. [Full Text] [PDF]

				M. M. Mello and T. A. Brennan Legal Concerns and the Influenza Vaccine Shortage JAMA, October 12, 2005; 294(14): 1817 - 1820. [Full Text] [PDF]

				P. Danzon and N. S. Pereira Why Sole-Supplier Vaccine Markets May Be Here To Stay Health Aff., May 1, 2005; 24(3): 694 - 696. [Abstract] [Full Text] [PDF]